| Literature DB >> 29898648 |
Seyed Mostafa Parizadeh1, Maryam Ghandehari1, Motahareh Heydari-Majd1, Sima Seifi1, Ramin Mardani1, Seyed Mohamadreza Parizadeh1, Majid Ghayour-Mobarhan1, Gordon A Ferns2, Seyed Mahdi Hassanian1,3,4, Amir Avan1,5.
Abstract
Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Cardiovascular disease; Toll-like receptors; atherogenesis; immune system; signaling pathway; stroke.
Mesh:
Substances:
Year: 2018 PMID: 29898648 DOI: 10.2174/1381612824666180614090224
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116